Posted by Michael Wonder on 03 Oct 2023
Formycon and Fresenius Kabi announce EMA acceptance of the marketing authorisation application for FYB202, an ustekinumab biosimilar candidate
29 September 2023 - Formycon and its commercialisation partner Fresenius Kabi today announced that the EMA has accepted the marketing authorisation application for FYB202, a proposed biosimilar candidate to Stelara.
The reference medicinal product Stelara is approved for treatment of moderate to severe plaque psoriasis, Crohn’s disease, ulcerative colitis as well as active psoriatic arthritis.
